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Abstract
Objectives: To assess whether patients’ characteristics and 
healthcare resources consumption and costs were different be-
tween native and migrant populations in Switzerland.
Methods: All adult patients followed-up in the Swiss HIV-co-
hort study in our institution during 2000–2003 were consid-
ered. Patients’ characteristics were retrieved from the cohort 
database. Hospital and outpatient resource use were extracted 
from individual charts and valued with 2002 tariffs. 
Results: The 66 migrants were younger (29 ± 8 years versus 
37 ± 11, p < 0.001), less often of male gender (38 % versus 70 %, 
p < 0.001), predominantly infected via heterosexual contact 
(87 % versus 52 %, p < 0.01), with lower mean CD4 level at en-
rolment (326 ± 235 versus 437 ± 305, p = 0.002) than their 200 
native counterparts.
Migrants had fewer hospitalizations, more frequent outpatient 
visits, laboratory tests, and lower total cost of care per year of 
follow-up (€ 2’215 ± 4’206 versus 4’155 ± 12’304, p = 0.037). Re-
source use and costs were significantly higher in people with 
< 200 CD4 cell counts in both groups.
Conclusions: Migrant population had more advanced disease, 
more outpatient visits but less hospitalizations, resulting in 
lower costs of care when compared with native population.
Keywords: Migration – HIV infection – Patient characteristics – 
Resource use – Costs.
The AIDS pandemic imposes considerable but uneven burden 
on all healthcare systems in the world. In developed coun-
tries, such as the United States of America, total costs of 
AIDS treatment amount to less than 1 % of direct personal 
healthcare expenses in the country, despite the widespread 
use of expensive anti-retroviral therapy (ART).1 As ART has 
been shown to substantially decrease mortality by delaying or 
even averting development of full blown AIDS,2 the issue at 
stake is more one of financing this treatment than one of costs 
of care. On the other hand, in developing countries, limited 
healthcare budgets cannot afford the provision of these ex-
pensive drugs. As a consequence, disease progression more 
closely follows the natural history of the disease, and mortal-
ity is high.3,4,5
In countries with immigration from countries with high inci-
dence and prevalence rates of AIDS, two populations coexist: 
the native population, with early detection of seropositivity 
and timely initiation of ART, and the migrant population, with 
late detection of the disease, and sometimes late initiation of 
antiretroviral triple therapy.
In Switzerland, HIV infected persons followed in one of sev-
en study centers are continuously enrolled in the Swiss HIV 
cohort study since 1988. This cohort showed an increasing 
proportion of migrants from Sub-Saharian Africa, ranging 
from 0.9 % before 1989 to 11.9 % in the 1997–2001 period. 
These patients were younger, had a lower median CD4 cell 
count at enrolment, were predominantly female and have 
been infected by heterosexual intercourse. Altogether, these 
patients accounted for 22.5 % of newly detected HIV infec-
tions in 2000 in Switzerland, representing only 0.3–0.4 % of 
the Swiss population. The Swiss HIV cohort study showed 
that there was no difference in adherence to ART, progression 
to AIDS or survival up to 48 months after starting treatment.6 
However, a direct comparison between patients’ characteris-
tics and healthcare resource use and costs in migrant and na-
tive populations has never been studied. We therefore used 
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the data from the patients recruited in our center to answer 
this question and discuss potential clinical and public health 
implications.
Methods
Data from the patients included in the Swiss HIV cohort study 
in our institution during the year 2000–2003 and followed-up 
at our institution were extracted from the central database. 
This database records, among other variables, age, gender, 
origin, route of infection, and CD4 cell count at enrolment. 
These patients are assessed twice a year with standard labo-
ratory tests, and general information on their treatment, the 
need for hospitalization for any reason, including pregnancy, 
is recorded.
Patients were selected if their origin was coded as European 
(native group), or Sub-Saharian country (migrant group). A 
few patients from other parts of the world were excluded. 
Hospital resource use, such as length of stay, number and type 
of diagnostic and therapeutic procedures, was extracted from 
the hospital information system, and outpatient resource use, 
such as number of visits and number and type of diagnostic 
and therapeutic procedures, was extracted from the individual 
charts of the outpatient clinics.
Hospital costs were computed from the analytic accounting 
system of the hospital, and outpatient visits, laboratory test 
and diagnostic and therapeutic procedures from official tariffs 
for the year 2002. Cost figures were converted from Swiss 
francs (CHF) to Euros (€) at the 2002 exchange rate of 1 CHF 
= 0.67 €.
Data were further stratified by CD4 cell counts (< 200, 200–
500, > 500). Finally, the whole analysis was repeated for the 
patients infected by heterosexual contact. Comparison of 
resource use and cost was again carried out between the 2 
groups of patients. 
As this study only observed current practice and did not in-
volve patients directly, no ethics committee approval nor pa-
tient consent was needed 
Comparisons of discrete data were carried out with the Stu-
dent t-test, for normally distributed variables, and with Mann-
Whitney U-test otherwise. Comparisons of proportions were 
carried out with Chi-square tests. The impact of CD4 cell 
counts on both resource consumption and cost was assessed 
by one-way analysis of variance (ANOVA). Statistical signifi-
cance was assumed for p value < 0.05.
Results
The native population was made of 200 people, predominant-
ly male (70 %), who had acquired their infection mainly by 
heterosexual contact (42 %), by having sex with men (MSM) 
(26 %) and by intra-venous drug use (IVDU) (28 %). The ma-
jority of them came from Switzerland, France or Germany 
(174 of them, 87 %), while the others came from Italy, Spain 
or Portugal. On the other hand, the migrant population was 
made of 66 people of Sub-Saharian origin, predominantly fe-
male (62 %), infected by heterosexual contact (87 %). They 
were statistically younger (29 ± 8 versus 37 ± 11 years) and 
had lower CD4 cell counts at enrolment (326 ± 235 versus 
439 ± 305), and a higher percentage of them had CD4 cell 
counts < 200 (35 % versus 26 %). Detailed patients’ character-
istics are displayed in Table 1.
Detailed per patient average resource consumption is dis-
played in Table 2. The native group tended to be hospitalized 
Table 1. Distribution of patients’ characteristics in the native and migrant groups treated at Lausanne University Hospital (CHUV) between 2000 and 
2003.
Characteristics Natives
(n = 200)
Migrants
(n = )
p value
Mean age (SD)  37  (11)  29   (8) < 0.001
Male gender (%) 140  (70)  25  (38) < 0.001
Infection route (%)   < 0.001
heterosexual  84  (42)  57  (87)
homosexual  52  (26)   0   ()
drug addiction  56  (28)   1   (2)
other   8   (4)   8  (12)
CD4 blood level
Mean CD4 level at enrolment (SD) 439 (305) 326 (235) 0.002
> 500 (%)  79  (40)  12  (18) 0.007
200–500 (%)  69  (34)  31  (47)
< 200 (%)  52  (26)  23  (35)
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more often, while the migrant group had significantly more 
outpatient visits and laboratory tests per year. Respective per 
patient average costs of care are displayed in Table 3. Mean 
hospital cost was higher in the native population, but was 
highly variable between the different individuals, especially 
among IVDU patients, so that the difference between the 
two groups did not reach statistical significance. On the other 
hand, migrants’ mean cost of outpatient care was statistically 
Table 2. Distribution of per patient average health care resource use in the native and migrant groups treated at Lausanne University Hospital 
(CHUV) between 2000 and 2003, over the whole observation period and by year of follow-up.
Resource use Natives
(n = 200)
Migrants
(n = )
p value
Mean (SD) Mean (SD)
Length of follow-up (years)  2.4  (0.7)  2.2  (0.8) 0.223
Hospitalisations
Number of stays  2.5  (3.0)  1.5  (0.6) 0.698
Episode length of stay (days)  4.2 (12.4)  3.5  (8.7) 0.775
Total length of stay (days)  7.7 (22.8)  3.5  (7.7) 0.201
Outpatient care
Visits  9.2  (7.6) 11.5  (7.0) 0.009
Laboratory tests 26.1 (20.6) 30.5 (19.5) 0.086
Imaging  0.6  (1.2)  0.5  (1.2) 0.546
Functional tests  0.1  (0.5)  0.1  (0.6) 0.266
Outpatient care/year of follow-up
Visits  3.9  (3.3)  5.2  (2.9) < 0.001
Laboratory tests 10.7  (8.8) 13.8  (0.2) 0.008
Imaging  0.2  (0.6)  0.2  (0.5) 0.744
Functional tests  0.1  (0.3)  0.1  (0.4) 0.260
Table 3. Distribution of per patient average health care costs in the native and migrant groups treated at Lausanne University Hospital (CHUV) 
between 2000 and 2003, over the whole observation period and by year of follow-up.
Cost (Euros) Natives
(n = 200)
Migrants
(n = )
p value
Mean (SD) Mean (SD)
Length of follow-up (years) 2.4 (0.7) 2.2 (0.8) 0.223
Hospitalisations
Hospital cost 5‘986 (18‘352) 2‘746 (6‘583) 0.854
Outpatient care
Visits 399 (329) 500 (303) 0.009
Laboratory tests 759 (591) 907 (637) 0.108
Imaging 149 (459) 108 (412) 0.523
Functional tests 29 (100) 21 (107) 0.194
Total outpatient care 1‘336 (1‘108) 1‘535 (1‘063) 0.114
Total cost of care 7‘323 (18‘543) 4‘281 (6‘745) 0.200
Cost/year of follow-up
Hospitalisations
Hospital cost 3‘595 (12‘219) 1‘533 (4‘044) 0.789
Outpatient care
Visits 170 (144) 225 (127) < 0.001
Laboratory tests 318 (249) 408 (303) 0.022
Imaging 58 (176) 42 (139) 0.664
Functional tests 14 (52) 13 (85) 0.181
Total outpatient care 560 (458) 688 (437) 0.009
Total cost of care 4‘154 (12‘304) 2‘221 (4‘206) 0.037
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significantly higher for visits and laboratory tests and total 
outpatient care, particularly when computed as per patient 
average costs per year. Altogether, total cost of care was sta-
tistically significantly higher in the native patient population, 
due to the higher weight of hospital costs as compared with 
outpatient costs. 
Both resource use and costs of care were significantly higher 
for the group with the lowest CD4 cell counts in both native 
and migrant populations (Figure 1). However, the only statis-
tically significant difference in direct comparison between the 
native and migrant group was observed in per patient average 
costs per year for outpatient care in the CD4 cell counts range 
of 200–500 (p = 0.045).
When analysis was repeated with only the populations in-
fected by heterosexual contact, patients characteristics such 
as age, gender, origin, route of infection, and CD4 cell count 
at enrolment remained similar to those of the initial popu-
lation in each group. Hospitalization rates were now simi-
lar between the 2 groups, for the number of stays (native 
population 1.7 ± 2.0 vs migrants 1.6 ± 0.7, p = 0.169), mean 
length of stay (natives 4.1 ± 14.7 days vs migrants 3.9 ± 9.3 
days, p = 0.726), and total length of stay (natives 3.1 ± 10.1 
days vs migrants 3.1 ± 6.4 days, p = 0.108). Migrants had 
always statistically significantly more outpatient visits per 
year of follow-up (natives 4.1 ± 3.7 vs migrants 5.2 ± 3.0, p 
= 0.009), and a trend for more laboratory tests than the na-
tive population (natives 10.9 ± 8.3 vs migrants 13.3 ± 8.0, p 
= 0.061). Again, resource use and cost of care were statisti-
cally significantly higher in patients with CD4 cell counts 
< 200, in both populations (Figure 2). Only one statistically 
significant difference in direct comparison between the na-
tive and migrant groups was observed in per patient average 
costs per year for hospital care in the CD4 cell counts range 
of > 500 (p = 0.014).
Discussion
This study underscores the fact that migrants from Sub-Sahar-
ian Africa in the Swiss HIV cohort study at our institution are 
identified and enter medical care at more advanced degrees 
of immunosuppression. While they use more health care re-
sources and have significantly higher outpatient care costs 
than their counterpart, they generate smaller hospital costs. 
This difference has to be ascribed to longer hospital stays in 
native IVDUs patients. However, the main trigger to increas-
ing resource consumption and cost in both groups was low 
CD4 cell counts. As health care resource use is highly vari-
able between patients over a long term basis, and as our pa-
tients had different length of follow-up, costs were expressed 
as per patient average costs by year, thus better exhibiting the 
differences between the 2 groups.
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Figure 1. Average yearly cost of hospitalization, outpatient visits, and total costs of care for natives and migrants HIV- infected patients treated at 
Lausanne University Hospital (CHUV) between 2000 and 2003, by CD4 cell counts.
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Figure 2. Average yearly cost of hospitalization, outpatient visits, and total costs of care for natives and migrants heterosexually HIV- infected 
patients treated at Lausanne University Hospital (CHUV) between 2000 and 2003, by CD4 cell counts.
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Several studies have assessed the healthcare resource use and 
cost of AIDS in different countries, using different methods. 
In America, HIV-infected patients accounted for 1.4 visits per 
person per month, while 30 % had at least one visit to the 
emergency department and 20 % were hospitalized for 10.4 
days over a period of 6 months; 79 % were treated with ART.1 
In Canada, a cohort of patients followed between 1995–2001 
showed an increase in antiretroviral therapy from 30 to 69 %, 
while in-patient care decreased from 26 % to 10 %, outpatient 
care from 27 % to 14 %, and home care from 8 % to 3 %, indi-
cating a shift in treatment efficacy.7
In Europe, a study carried out in 10 centers in England in 
1996 showed that patients were hospitalized an average of 20 
days per year, while the number of outpatient visits and cost 
increased from asymptomatic to symptomatic AIDS (from £ 
4’695 to £ 20’358 per year).8 Similar results were found in 
Belgium on the basis of a diary held by 41 patients9 and in 
Italy in a multicentric prospective cohort of 483 patients fol-
lowed from 1997 to 1998.10 The most impressive comparison 
of two cohorts observed over 6 months in 1994 and 1998 in 
a multicentric prospective study showed a dramatic decrease 
in mortality from 33.8 % to 3.9 %, in hospital admissions 
from 1.7 % to 0.8 %, in length of stay from 28.1 days to 12.6 
days, matched by a decrease in direct costs from € 15’390 
to € 11’465. In addition, HIV-infected patients treated with 
antiretroviral regimens had a better health-related quality of 
life and were dependent to a smaller extent (6.8 % versus 
1.4 %). Distribution of the type of costs showed that drug 
acquisition costs had dramatically increased from 12.8 % to 
63.5 % while hospital cost decreased from 45.3 % to 26.1 %, 
outpatient care from 33.2 % to 10.4 %, and home care disap-
peared.2 All these data confirmed that introduction of antiret-
roviral therapy was effective, even if it markedly increased 
cost of treatment.
Curiously, no study focused on migrant populations, except 
in the Swiss HIV cohort study,6 which showed an increasing 
proportion of migrants from Sub-Saharian countries, which 
were younger, more often female, and infected by heterosexu-
al intercourse, had low CD4 cell counts at inclusion, but equal 
access to ART, and similar prognosis, as HIV positive people 
from North Western Europe.
Extrapolating data from other studies, which showed an 
adverse correlation between CD4 cell counts and health re-
source utilization and cost, it would be tempting to assume 
that systematic screening might identify HIV positive patients 
earlier and hence give them access to effective therapy in a 
more timely way. However, past modelisation of the cost of 
pediatric infection and AIDS showed that it will be increased 
if mothers were systematically screened while at the same 
time increasing the life expectancy and the AIDS-free life ex-
pectancy of children.11 Similarly, another study claimed that 
cost savings due to highly effective treatment would be illu-
sory if this treatment could not prevent or substantially delay 
the progression to full-blown AIDS.12 This perspective has 
been achieved, as a recent study showed that median survival 
can now be expected to be more than 35 years for a young 
person diagnosed with HIV infection.13 All cost-effectiveness 
or cost-utility studies have concluded that the cost-effective-
ness or cost-utility ratios amounted to about US$ 10–55’000 
per life year or quality-adjusted life-year gained in patients 
from developed countries.12 This is likely to be the case in 
migrants as well.14 All these results prompted the Center for 
Disease Control to revise its recommendations for HIV test-
ing of adults, adolescents, and pregnant women in health care 
settings, and advocate wide and repeated screening.15
Our study has several limitations. It was carried out in only 
one center, and hence on a limited number of patients. It did 
not include health care resource use and costs incurred by 
patients visiting other physicians than our institution. As the 
native population is more likely to have used this kind of care 
than migrants, this factor might explain part of the observed 
difference in the number of outpatient visits, laboratory tests, 
and hence costs between the 2 groups. In addition, our study 
did not focus on drug acquisition costs which were shown to 
amount to a substantial share in other studies. However, as 
patients in the Swiss HIV cohort study had no difference in 
access to this therapy,6 it is unlikely that this omission might 
markedly distort the results. Finally, it focuses only on direct 
medical cost from a payer’s perspective. 
However, even if the ability to generalize the findings of this 
study is limited, it provides a first look for Switzerland into 
this highly controversial and politically sensitive subject. The 
issues linked with equity of access to voluntary confidential 
testing for early HIV diagnosis and type of health care pro-
vided should be further studied. Although screening was re-
cently publicly discussed in the United States, underlying the 
potential conflict existing between public health and civil lib-
erties,16,17 this debate still has to take place in other countries.
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Résumé
Objectifs: Évaluer si les caractéristiques des patients et leur 
consommation de ressources et coût diffèrent entre popula-
tion locale et migrante en Suisse.
Méthodes: Les patients adultes de la cohorte HIV Suisse suivis 
dans notre institution. Leurs caractéristiques ont été extraites 
des données de la cohorte, leur utilisation de ressources hospi-
talières et ambulatoires de leurs dossiers et valorisées aux tarifs 
2002. 
Résultats: Les 66 migrants étaient plus jeunes (29 ± 8 ans versus 
37 ± 11, p < 0.001), moins souvent mâles (38 % versus 70 %, p 
< 0.001), surtout infectés par contact hétérosexuel (87 % ver-
sus 52 %, p < 0.01), avec des comptes CD4 plus bas à l’inclusion 
(326 ± 235 versus 437 ± 305, p = 0.002) que les 200 locaux.
Les migrants avaient moins d’hospitalisations, plus de visites 
ambulatoires, examens de laboratoire et des coûts annuels de 
suivi plus bas (€ 2’215 ± 4’206 versus 4’155 ± 12’304, p = 0.037). 
L’utilisation de ressources et les coûts étaient significativement 
plus élevés chez les patients avec un compte CD4 < 200 dans 
les 2 groupes. 
Conclusions: Les migrants présentent une maladie plus avan-
cée, plus de visites ambulatoires, mais moins d’hospitalisations, 
menant à des coûts de prise en charge inférieurs à ceux de la 
population locale.
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